Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

tarsus pharmaceuticals inc - TARS

TARS

Close Chg Chg %
81.70 -0.35 -0.43%

Closed Market

81.35

-0.35 (0.43%)

Volume: 452.64K

Last Updated:

Dec 12, 2025, 4:00 PM EDT

Trade Now

Company Overview: tarsus pharmaceuticals inc - TARS

TARS Key Data

Open

$82.33

 Day Range

80.51 - 83.34

52 Week Range

38.51 - 85.25

 Market Cap

$3.45B

Shares Outstanding

42.45M

 Public Float

39.12M

Beta

0.75

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.01

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

419.39K

  

TARS Performance

1 Week
 
 -0.51%
 
1 Month
 
 11.56%
 
3 Months
 
 64.81%
 
1 Year
 
 54.95%
 
5 Years
 
 63.95%
 

TARS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About tarsus pharmaceuticals inc - TARS

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

TARS At a Glance

Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road
Irvine, California 92618
Phone 1-949-409-9820 Revenue 182.95M
Industry Pharmaceuticals: Major Net Income -115,554,000.00
Sector Health Technology 2024 Sales Growth 948.622%
Fiscal Year-end 12 / 2025 Employees 323
View SEC Filings

TARS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 11.381
Price to Book Ratio 9.457
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -15.612
Enterprise Value to Sales 10.184
Total Debt to Enterprise Value 0.039

TARS Efficiency

Revenue/Employee 566,417.957
Income Per Employee -357,752.322
Receivables Turnover 3.807
Total Asset Turnover 0.569

TARS Liquidity

Current Ratio 4.425
Quick Ratio 4.392
Cash Ratio 3.615

TARS Profitability

Gross Margin 92.989
Operating Margin -65.902
Pretax Margin -63.16
Net Margin -63.16
Return on Assets -35.91
Return on Equity -54.827
Return on Total Capital -38.909
Return on Invested Capital -44.046

TARS Capital Structure

Total Debt to Total Equity 32.268
Total Debt to Total Capital 24.396
Total Debt to Total Assets 19.201
Long-Term Debt to Equity 31.997
Long-Term Debt to Total Capital 24.191
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Tarsus Pharmaceuticals Inc - TARS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
57.03M 25.82M 17.45M 182.95M
Sales Growth
- -54.73% -32.42% +948.62%
Cost of Goods Sold (COGS) incl D&A
2.08M 955.00K 1.59M 12.83M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
606.00K 789.00K 877.00K 1.23M
Depreciation
606.00K 789.00K 744.00K 685.00K
Amortization of Intangibles
- - 133.00K 540.00K
-
COGS Growth
+743.50% -53.98% +66.81% +705.15%
Gross Income
54.95M 24.86M 15.85M 170.13M
Gross Income Growth
+22,438.21% -54.76% -36.23% +973.09%
Gross Profit Margin
+96.36% +96.30% +90.87% +92.99%
2021 2022 2023 2024 5-year trend
SG&A Expense
67.11M 87.57M 159.01M 290.70M
Research & Development
41.71M 42.62M 50.31M 53.39M
Other SG&A
25.40M 44.95M 108.70M 237.31M
SGA Growth
+151.00% +30.49% +81.58% +82.81%
Other Operating Expense
- - - -
-
Unusual Expense
1.58M 769.00K (376.00K) 2.15M
EBIT after Unusual Expense
(13.73M) (63.48M) (142.78M) (122.71M)
Non Operating Income/Expense
(37.00K) 3.58M 10.23M 15.01M
Non-Operating Interest Income
36.00K 3.50M 10.34M 15.01M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 2.20M 3.35M 7.85M
Interest Expense Growth
- - +52.16% +134.58%
-
Gross Interest Expense
- 2.20M 3.35M 7.85M
Interest Capitalized
- - - -
-
Pretax Income
(13.77M) (62.09M) (135.89M) (115.55M)
Pretax Income Growth
+48.63% -350.88% -118.85% +14.97%
Pretax Margin
-24.15% -240.53% -778.89% -63.16%
Income Tax
- - 55.00K (4.00K)
-
Income Tax - Current - Domestic
- - - (4.00K)
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(13.83M) (62.09M) (135.89M) (115.55M)
Minority Interest Expense
- - - -
-
Net Income
(13.83M) (62.09M) (135.89M) (115.55M)
Net Income Growth
+48.43% -349.06% -118.86% +14.97%
Net Margin Growth
-24.25% -240.51% -778.89% -63.16%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(13.83M) (62.09M) (135.89M) (115.55M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(13.83M) (62.09M) (135.89M) (115.55M)
EPS (Basic)
-0.6727 -2.522 -4.6248 -3.0729
EPS (Basic) Growth
+49.01% -274.91% -83.38% +33.56%
Basic Shares Outstanding
20.55M 24.62M 29.38M 37.60M
EPS (Diluted)
-0.6727 -2.522 -4.6248 -3.0729
EPS (Diluted) Growth
+49.01% -274.91% -83.38% +33.56%
Diluted Shares Outstanding
20.55M 24.62M 29.38M 37.60M
EBITDA
(11.55M) (61.92M) (142.28M) (119.34M)
EBITDA Growth
+56.80% -436.08% -129.77% +16.12%
EBITDA Margin
-20.26% -239.86% -815.50% -65.23%

Snapshot

Average Recommendation BUY Average Target Price 86.111
Number of Ratings 10 Current Quarters Estimate -0.084
FY Report Date 12 / 2025 Current Year's Estimate -1.469
Last Quarter’s Earnings -0.30 Median PE on CY Estimate N/A
Year Ago Earnings -3.07 Next Fiscal Year Estimate 1.748
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 5 10 8
Mean Estimate -0.08 -0.01 -1.47 1.75
High Estimates 0.06 0.43 -1.31 3.21
Low Estimate -0.68 -0.24 -2.09 0.59
Coefficient of Variance -274.55 -5,099.79 -15.39 57.83

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 7
OVERWEIGHT 1 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Tarsus Pharmaceuticals Inc - TARS

Date Name Shares Transaction Value
Mar 24, 2025 Bryan Wahl General Counsel 14,497 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Sesha Neervannan Chief Operating Officer 16,296 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Sesha Neervannan Chief Operating Officer 5,097 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Sesha Neervannan Chief Operating Officer 87,265 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Dianne Whitfield Chief Human Resources Officer 21,527 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Dianne Whitfield Chief Human Resources Officer 14,497 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Dianne Whitfield Chief Human Resources Officer 4,463 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Dianne Whitfield Chief Human Resources Officer 53,066 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Jeffrey S. Farrow See Remarks 26,155 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Sesha Neervannan Chief Operating Officer 24,060 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Bryan Wahl General Counsel 61,398 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Bobak Azamian President/CEO and Board Chair; Director 69,364 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Bobak Azamian President/CEO and Board Chair; Director 33,950 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Bobak Azamian President/CEO and Board Chair; Director 11,300 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Bryan Wahl General Counsel 21,527 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Bobak Azamian President/CEO and Board Chair; Director 77,851 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Bryan Wahl General Counsel 4,790 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Jeffrey S. Farrow See Remarks 24,060 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Aziz Mottiwala Chief Commercial Officer 4,790 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Aziz Mottiwala Chief Commercial Officer 16,296 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Tarsus Pharmaceuticals Inc in the News